Article Text

Download PDFPDF

Response to: ‘Correspondence on ‘Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank’’ by Takei et al
  1. Gabriela Sandoval-Plata1,2,3,
  2. Kevin Morgan3,
  3. Abhishek Abhishek1,2
  1. 1Academic Rheumatology, University of Nottingham, Nottingham, UK
  2. 2Nottingham Biomedical Research Centre, NIHR, Nottingham, UK
  3. 3Human Genetics, School of Life Sciences, University of Nottingham, Nottingham, UK
  1. Correspondence to Gabriela Sandoval-Plata, Academic Rheumatology, University of Nottingham, Nottingham, UK; mbxgs2{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Takei et al conducted a genome-wide association study (GWAS) in European individuals with gout versus asymptomatic hyperuricaemia controls. They reported nine independent genetic variants in or near ABCG2, SLC2A9, GCKR, ADH1B, SLC22A11, PDX1, MLXIPL and CNBD1 associated with gout using ‘a more stringent’ threshold of r2<0.01 for linkage disequilibrium (LD) clumping. Compared with our study, they found three additional loci in PDX1 (rs182200427), MLXPIL (rs7805504) and CNBD1 (rs181604403) that were not included in the non-imputed UK Biobank dataset used in our study. And more importantly, they reported a single SNP in ABCG2 (ie, rs2231142) locus associated with gout after conditioning on rs2231142.1

In our analysis, we reported 13 independent genetic variants mapped to ABCG2, SLC2A9, SLC22A11, GCKR, ADH1B, MEPE, PPM1K-DT and LOC105377323. Eight of which are located in chromosome 4, near the ABCG2 locus. To determine independent associations, we selected a r2<0.1 for LD clumping, which is lower than the standard threshold (r2<0.2) used in many GWAS, and a p value <5.0×10−8. We performed further analyses looking at pairwise LD comparisons among these loci, using LDlinkR2 with the 1000 Genomes dataset as the reference panel. Additionally, LD clumping was also performed using PRSice-23 for the polygenic risk score generation, using the same UK Biobank dataset as the reference panel for LD estimations. Both analyses retained the 13 single nucleotide polymorphisms (SNPs) as independent associations, and the LD pattern in our supplementary figure 2 did not prompt us to conduct conditional analyses.

We acknowledge that using a more stringent r2 cut-off reduces the number of independent variants. However, ABCG2 gene has shown evidence of complex LD structure. Additional SNPs within the same locus have been associated to gout. For instance, rs3114018 (r2>0.2 with rs7672194, reported in our study) located in a different haplotype block from rs2231142 has been related to gout risk.4

Moreover, a study by Zelenchuk et al reported that changes to the N-terminal region of MEPE contribute to hyperuricaemia and a reduction in fractional excretion of uric acid in a mouse model.5 Therefore, the role of MEPE in purine metabolism merits additional research to identify if genetic variants within this locus contribute to serum urate variation either by regulating nearby urate transporter genes, or via other effects such as those on renal phosphate handling.

Deep sequencing of the ABCG2 gene and upstream and downstream regions to capture MEPE, PPM1K-DT and LOC105377323 is required to determine underlying functional rare variants that could influence gout risk.

The final comment of Takei and colleagues is correct. We highlighted the closest gene to the significant variant at each locus, as is tradition, but we acknowledge that it may be any within the locus which we should have stated clearly.

We would like to take this opportunity to thank Takei and colleagues for undertaking this additional work.

Ethics statements



  • Handling editor Josef S Smolen

  • Twitter @gabylusp

  • Contributors All authors contribute to the preparation and revision for important intellectual content of this work, and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests Prof AA has received departmental research grants from AstraZeneca and Oxford Immunotec, speaker bureau fees from Menarini, scientific meeting support from Pfizer, author royalties from UpToDate and Springer and has consulted for Inflazome unrelated to this work.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles